Nexstim Plc ("Nexstim" or "Company") Resolutions of the

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Nexstim Plc ("Nexstim" or "Company") Resolutions of the annual general meeting of shareholders

Helsinki, 31 March 2015, 12:00 pm Nexstim Plc (NXTMH:HEX, NXTMS:STO), a medical technology company aiming to improve rehabilitation for stroke patients with the use of non-invasive brain stimulation, announces that the following resolutions were adopted at its annual general meeting of shareholders held today on 31 March. The annual general meeting of shareholders of Nexstim Plc adopted the Company's financial statements, including the consolidated financial statements for the year 2014, and discharged the members of the Board of Directors and the Chief Executive Officer from liability. Dividend and handling of loss The general meeting decided that no dividend would be paid for the financial year 1 January 2014 - 31 December 2014 and that the loss of the financial year be added to the loss account. Composition and remuneration of the Board of Directors The general meeting resolved the number of the members of the Board of Directors at seven. Olli Riikkala, Ken Charhut, Ekaterina Smirnyagina, Juha Vapaavuori, Rene Kuijten, Juliet Thompson and Johan Christenson were elected to the Board; Olli Riikkala was elected as the chair and Johan Christenson as the deputy chair. The new Board member, Juliet Thompson, has spent approximately 20 years working as an investment banker and strategic advisor to healthcare companies in Europe.  She he has built a strong track record of advising companies on corporate strategy, equity and debt fundraisings and international M&A.  She is a Chartered Accountant ACA; Chartered Institute for Securities and Investment (ASCI); Bsc Economics (Bristol University).  Her experience includes roles at Oriel Securities, Nomura Code Securities, WestLB Panmure, ICI PLC, Deloitte and Touche and HM Treasury. The remuneration of the members of the Board of Directors was resolved as follows: €45,000 for the chair of the board, €36,000 for the members of the board domiciled in the USA, €18,000 for the members domiciled in Finland, and €27,000 for the members domiciled in Europe, outside Finland. The general meeting recommended that the members of the board invest half of the above- mentioned remuneration in the Company's shares. Further, the general meeting resolved that the members of the board committees domiciled in Finland be paid as follows for each committee meeting at which they are present: €1,000 for the chair of the committee and €500 for the other members of the committee. The members of the board committees domiciled in the USA will be paid as follows for each committee meeting at which they are present: €2,000 for the chair of the committee and €1,000 for the other members of the committee. The members of the board committees domiciled in Europe but outside Finland, will be paid as follows for each committee meeting at which they are present: €1,500 for the chair of the committee and €750 for the other members of the committee. It was decided that reasonable travel expenses of the ordinary members of the board be compensated against receipts. Election of the auditor and auditor's fee PricewaterhouseCoopers Oy, an auditing firm approved by the Finnish Chambers of Commerce, was re-elected as the auditor with Martin Grandell acting as the auditor-in-charge. The auditor will be paid a reasonable fee in accordance with an invoice approved by the Company. Proposal of the Board of Directors for authorising the Board of Directors to decide on the repurchase of the company's own shares The general meeting decided that the Board of Directors be authorised to decide on the repurchase of the Company's own shares as follows: The amount of own shares to be repurchased will not exceed 1,069,613 shares, which corresponds to approximately 15 per cent of all of the shares in the Company. For the sake of clarity, it was noted, however, that the Company together with its subsidiaries cannot simultaneously possess more than 10 per cent of its registered amount of shares. The Board of Directors will decide on how shares will be repurchased. Shares can be repurchased using, inter alia, derivatives. Own shares can also be repurchased otherwise than in proportion to the shareholdings of the shareholders (directed repurchase). The minimum price of the shares repurchased is the lowest listed market price of the share during the period of authorisation and, correspondingly, the maximum price is the highest listed market price of the share during the period of authorisation. If the Board of Directors uses the authorisation granted to it by the general meeting, it will follow the guidelines for the repurchase of a company's own shares of the Helsinki Stock Exchange, as applicable. Own shares can be repurchased, inter alia, to limit the dilutive effects of share issues carried out in connection with possible acquisitions, to develop the Company's capital structure, to be transferred in connection with possible acquisitions, to be used in the Company's incentive arrangements or to be cancelled, provided that the repurchase is in the interest of the Company and its shareholders. The authorisation is effective for 18 months from the resolution of the general meeting. Authorising the Board of Directors to decide on the issuance of shares as well as the issuance of special rights entitling to shares The general meeting authorised the Board of Directors to decide on the issuance of shares as well as the issuance of special rights entitling to shares referred to in chapter 10 of the Finnish Companies Act as follows: Shares potentially issued by virtue of the special rights entitling to shares are new shares or shares held by the Company. The maximum amount of shares potentially issued by virtue of the special rights entitling to shares is 1,069,613 shares, which corresponds to approximately 15 per cent of all of the shares in the Company. Shares or special rights entitling to shares can be issued in one or more parts. The Board of Directors is authorised to decide on all the conditions of the issuance of shares and special rights entitling to shares. The issuance of shares and special rights entitling to shares may be carried out in deviation from the shareholders' pre-emptive rights by way of a directed issue, provided that there is a weighty financial reason for doing so. The authorisation may also be used for incentive arrangements and to pay remuneration to the board members. The proposed authorisation annuls the authorisations resolved and registered during the previous general meetings regarding the issuance of shares and special rights entitling to shares, as well as to the transfer of the Company's own shares. The authorisation is valid for three (3) years from the resolution of the general meeting. Board's proposal for an amendment of the articles of association The general meeting decided that section 4 of the articles of association will be amended as follows: "Section 4. Representation rights The right to represent the Company is vested in the chair of the Board of Directors and the Chief Executive Officer, each one alone, and two jointly acting members of the board of directors, as well as the persons authorised by the Board of Directors to represent the Company, two of them acting jointly, or each such person acting together with the chair of the Board of Directors, a member of the Board of Directors or the Chief Executive Officer. The Board of Directors resolves on granting representation rights and procurations." Minutes of the general meeting The minutes of the general meeting will be published on, or by, 14 April 2015, on Nexstim's website. NEXSTIM PLC Janne Huhtala, CEO Further information is available on the website www.nexstim.com or by contacting: Nexstim                                        +358 (0)40 8615046 Janne Huhtala, CEO janne.huhtala@nexstim.com UB Capital Oy (certified adviser)                                        +358 (0)9 2538 0225 Consilium Strategic Communications                                        +44 (0)20 3709 5700 Mary-Jane Elliott / Ivar Milligan nexstim@consilium-comms.com About Nexstim Plc Nexstim is a medical technology company founded in 2000 in Finland aiming to improve rehabilitation for stroke patients. Nexstim has pioneered its technology as a diagnostic tool for brain surgery with its Navigated Brain Stimulation (NBS) system. It is the first and only FDA cleared and CE-marked system based on the navigated transcranial magnetic stimulation (nTMS) for pre-surgical mapping of the speech and motor cortices of the brain. Based on the same technology platform, the company has developed a device called Navigated Brain Therapy (NBT®) for use in the rehabilitation of stroke patients. During the first half of 2014, Nexstim started a two-year Phase III key study in 12 locations in the USA with the aim of demonstrating the efficiency of the NBT® equipment and receiving FDA clearance to market said equipment for post-acute rehabilitation of stroke patients in the USA. Nexstim shares have been listed on Nasdaq First North Finland and Nasdaq First North Sweden. Further information is available on the website www.nexstim.com. [HUG#1907634]

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Human Frontier Mission Puts AI Research on Display

Updated Category News Views 45

A laboratory notebook is about to become the real product in this AI experiment. Human Frontier Mission, or HFM, says it will launch globally on Nov. 24, opening a research program where domain specialists frame scientific and engineering problems while autonomous AI agents develop and test possible answers. The unusual bit is not merely handing models difficult work. It...

Continue Reading
WaterField’s Nova Case Bets on Better Handheld Carry

Updated Category News Views 182

Tiny handhelds have spawned a surprisingly fussy luggage problem: protection without the clown-show aesthetic. WaterField Designs is taking a clean swing at that with a custom case for the Retroid Pocket Nova, a sleeve-like carrier built around the device rather than some generic pouch that leaves everything rattling around inside. This is not a market-moving corporate...

Continue Reading
Domino's Probe Puts Franchise Disclosure Under Lens

Updated Category News Views 121

A franchisee's shuttered stores can turn cheerful unit-growth talk into a nasty accounting of credibility, and that is the uncomfortable territory Domino's now occupies. Kahn Swick & Foti has opened an investigation into whether Domino's officers and directors breached fiduciary duties or violated state or federal law. That is not a finding of misconduct. It is a legal...

Continue Reading
Kyverna Probe Reopens IPO Disclosure Questions for Investors

Updated Category News Views 93

Clinical-trial caveats have a nasty habit of becoming shareholder headaches years later. Kyverna Therapeutics is back in that uncomfortable zone after Kahn Swick & Foti said it has opened an investigation into whether the company’s officers and directors breached fiduciary duties or otherwise violated state or federal law. For holders of KYTX, this is not a verdict and...

Continue Reading
California Rideshare Data Exposes an Insurance Gap

Updated Category News Views 52

Three California counties carried an outsized share of rideshare traffic, and the insurance fine print is where this story gets uncomfortable. A review by Mendez & Sanchez says Los Angeles, San Francisco, and San Diego counties accounted for nearly two-thirds of statewide rideshare trips between September 2019 and August 2020. That is an old snapshot, sure, but it points...

Continue Reading
Anthropic's Leveraged ETFs Arrive After Wild Debut

Updated Category News Views 105

Nothing says a feverish new listing quite like leveraged products lining up before the opening-week confetti has settled. Anthropic priced its IPO at $83 on November 18, raised roughly $81.3 billion, then opened Nasdaq trading at $111.50 on November 19. That is an enormous gap between IPO price and first trade, and it tells investors the obvious thing: plenty of appetite...

Continue Reading
Sitting, Lymph Flow, and a Supplement Maker's Pitch

Updated Category News Views 104

By late afternoon, a chair can feel like it has quietly won the argument against your legs. PureHealth Research is leaning into that familiar heavy, puffy-legged feeling with a reminder about lymphatic flow—and, naturally, an eight-ingredient supplement positioned alongside it. The broad message is sensible. The sales layer needs the usual healthy squint. Movement Does...

Continue Reading
AMD Faces Fresh Scrutiny Over China Supply Exposure

Updated Category News Views 140

One nasty report can turn a chip giant’s supply chain into a flashing red light, and that is precisely the mess confronting Advanced Micro Devices investors this week. Shares fell more than 7.7% on November 19 after Hunterbrook Media published allegations involving China-linked sales, firmware and manufacturing relationships. Then, on November 20, shareholder-rights...

Continue Reading
California Initiative Puts Missed Diagnoses in Focus

Updated Category News Views 98

When Reassurance Turns Into a Risk A clean scan can become a dangerous lullaby when symptoms refuse to leave. That is the hard, unsettling territory behind Hodes Milman’s new Missed Diagnosis Project: California, launched November 20, 2026. The statewide effort focuses on breast cancer diagnostic failures: scans read as benign when more scrutiny was warranted, referrals...

Continue Reading
3TREES Tests a Bigger Asia-Pacific Growth Blueprint

Updated Category News Views 97

A bucket of paint rarely sounds strategic until it sits inside a regional supply chain. That is the useful part of 3TREES chairman and president Hong Jie's message from the Asia-Pacific Economic Cooperation CEO Summit in Shenzhen on November 17-18, 2026: coatings are not merely a commodity if the supplier can bring materials, energy savings, technical know-how and...

Continue Reading

Top 5 Most Recently Viewed Articles

Stellantis NV: Short Interest Shift Sparks Investor Sentiment Questions

Updated Category News Views 299

Stellantis NV's (NYSE:STLA) short interest saw a notable drop of 13.81% since its last report, now standing at 44.96 million shares sold short, or about 1.56% of all tradable shares. Sounds like good news, right? But hang on—this isn't just a free pass to pop the champagne. When we talk short interest, we're peeling back layers on market sentiment that can turn on a...

Continue Reading
Minerals Technologies Showcases Innovative PFAS Solutions at Symposium

Updated Category News Views 185

Minerals Technologies to Present at Gabelli Funds PFAS Symposium Minerals Technologies Inc. (MTI) is thrilled to announce its participation in the upcoming PFAS Symposium hosted by Gabelli Funds. This notable event is set to take place in New York City, bringing together key figures in the industry to discuss significant advancements and novel strategies for tackling...

Continue Reading
Morning Market Insights for Key Stocks: A Daily Review

Updated Category News Views 338

Daily Market Insights: Leading Stocks to Watch Good morning, traders. Today’s notes zero in on SPY, QQQ, AAPL, MSFT, NVDA, GOOGL, META, and TSLA—names that tend to steer the broader tape. Our read on price comes from a blend of key levels shaped by price action, trading volume, and options flow. We refresh these levels daily and share them with Market Clubhouse...

Continue Reading
Exploring the Evolving Landscape of Electric Vehicles in the U.S.

Updated Category News Views 224

The Current State of Electric Vehicles in the U.S. The electric vehicle (EV) landscape in the U.S. is experiencing transformative changes. As the country marks significant milestones in EV deployment, there are noteworthy gaps in infrastructure and consumer attitudes that need addressing. The third annual HERE-SBD EV Index reveals how far the U.S. has come, yet highlights...

Continue Reading
eBay's Legal Victory: Dismissal of Harmful Product Claims

Updated Category News Views 173

eBay's legal drama hit the news when the U.S. government slammed them with a lawsuit accusing the online giant of violating the Clean Air Act back in 2024. The crux? Selling products that supposedly helped folks skirt around those pesky auto pollution controls. You know how it is—desks buzzing about regulatory risks, and traders getting twitchy over such moves. The...

Continue Reading